Actualizado
Reviewed
Jun. 03, 2021
Appendix B: Drug Characteristics Tables
Characteristics of the gp120 Attachment Inhibitor
Generic Name (Abbreviation) Trade Name |
Formulation | Dosing Recommendations | Serum Half-Life | Elimination/ Metabolic Pathway | Adverse Events |
---|---|---|---|---|---|
Fostemsavir (FTR) Rukobia |
|
|
11 hours | Hydrolysis (esterases), CYP3A4 |
Nausea QTc prolongation was seen at 4 times the recommended dose. Use with caution in patients with preexisting heart disease, QTc prolongation, or concomitant use of medications that may prolong QTc interval. Transaminase elevation; transient bilirubin elevation Sleep disturbance, dizzines |
Key: CYP = cytochrome P; FTR = fostemsavir; PO = orally; QTc = corrected QT interval |
Appendix B: Drug Characteristics Tables
Characteristics of the gp120 Attachment Inhibitor
Generic Name (Abbreviation) Trade Name |
Formulation | Dosing Recommendations | Serum Half-Life | Elimination/ Metabolic Pathway | Adverse Events |
---|---|---|---|---|---|
Fostemsavir (FTR) Rukobia |
|
|
11 hours | Hydrolysis (esterases), CYP3A4 |
Nausea QTc prolongation was seen at 4 times the recommended dose. Use with caution in patients with preexisting heart disease, QTc prolongation, or concomitant use of medications that may prolong QTc interval. Transaminase elevation; transient bilirubin elevation Sleep disturbance, dizzines |
Key: CYP = cytochrome P; FTR = fostemsavir; PO = orally; QTc = corrected QT interval |
Download Guidelines
- Section OnlyPDF (169.95 KB)
- Full GuidelinePDF (5.07 MB)
- Recommendations OnlyPDF (229.24 KB)
- Tables OnlyPDF (939.48 KB)